News for PSTI Stock

Pluri CEO Issues Shareholder Update Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture Pluristem CEO Issues Shareholder Update Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19 Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform Pluristem CEO Issues Shareholder Update Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout Pluristem to Receive €20M Non-Dilutive Funding from the European Investment Bank Pluristem reports positive topline Phase I results in innovative hematology program, which is first to study PLX-R18 in humans Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel Pluristem CEO Issues Shareholder Update Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of Severe Diseases Including COVID-19 U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study Pluristem Recaps Investor & Analyst Call Reviewing European Investment Bank’s €50 Million Financing The European Investment Bank (EIB), EU Delegation to Israel, the Israel Innovation Authority, and Pluristem Cordially Invite the Public to an Online Signing Ceremony on April 30, 2020 Pluristem CEO Issues Shareholder Update on Clinical Programs Pluristem Announces Pricing of Its Registered Direct Offering for Aggregate Proceeds of $15 Million EIB signs collaboration with Israel Innovation Authority and €50 million financing agreement with Pluristem to develop therapies for COVID-19 and other unmet medical needs